Timothy Burns, MD, PhD: Emerging Trials in First-Line KRAS-Mutant NSCLC – SUNRAY-01

Dr. Burns discusses the recent advances in targeting KRAS mutations in patients with NSCLC. He describes the SUNRAY-01 trial, which is investigating the use of olomorasib plus pembrolizumab with or without chemotherapy vs standard of care in the first-line treatment of KRAS G12C-mutant NSCLC.